SNDX
Syndax Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology · US
$10.48
−26.66%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 289.4M | 172.4M | 23.7M | — | — |
| Cost of Revenue | 18.3M | 7.0M | 826.0K | — | — |
| Gross Profit | 271.2M | 165.4M | 22.9M | — | — |
| Operating Expenses | |||||
| R&D Expense | 273.0M | 258.8M | 241.6M | 163.0M | 118.5M |
| SG&A Expense | 172.8M | 179.7M | 120.9M | 66.9M | 33.3M |
| General & Admin Expense | 131.2M | 179.7M | 120.9M | 66.9M | 33.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 4.0M | — | — | — | — |
| Total Operating Expenses | 449.8M | 438.5M | 362.5M | 230.0M | 151.8M |
| Cost and Expenses | 468.1M | 445.4M | 363.4M | 230.0M | 151.8M |
| Operating Income (EBIT) | (178.6M) | (273.1M) | (339.7M) | (230.0M) | (151.8M) |
| Non-Operating | |||||
| Interest Income | 22.5M | 22.7M | 26.1M | 21.2M | 5.9M |
| Interest Expense | 90.2M | 33.8M | 4.9M | 208.0K | 3.1M |
| Net Interest Income | (67.7M) | (11.1M) | 21.2M | 21.0M | 2.7M |
| Other Non-Op Income/Expense | (30.8M) | (12.3M) | 20.9M | 20.6M | 2.4M |
| Non-Operating Income (excl Interest) | (59.4M) | (21.4M) | (25.8M) | (20.8M) | (5.6M) |
| EBT (Pre-Tax Income) | (209.5M) | (285.4M) | (318.8M) | (209.4M) | (149.3M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (209.5M) | (285.4M) | (318.8M) | (209.4M) | (149.3M) |
| Earnings from Cont. Ops | (209.5M) | (285.4M) | (318.8M) | (209.4M) | (149.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (209.5M) | (285.4M) | (318.8M) | (209.4M) | (149.3M) |
| Per Share | |||||
| Basic EPS | ($2.37) | ($3.29) | ($3.73) | ($2.98) | ($2.46) |
| Diluted EPS | ($2.37) | ($3.29) | ($3.73) | ($2.98) | ($2.46) |
| Revenue Per Share | $3.22 | $1.99 | $0.28 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 89.8M | 86.6M | 85.6M | 70.4M | 60.8M |
| Diluted Shares Outstanding | 89.8M | 86.6M | 85.6M | 70.4M | 60.8M |
| Profitability Metrics | |||||
| EBITDA | (119.3M) | (251.6M) | (313.8M) | (209.1M) | (146.2M) |
| D&A | 18.0K | 6.0K | 8.0K | 12.0K | 33.0K |
| EBIT | (119.3M) | (251.6M) | (313.8M) | (209.2M) | (146.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026